Newsletter | May 19, 2020

05.19.20 -- BioCardia CEO Talks Cell Therapy Heart Failure Trial

From The Editor

Hello Cell & Gene readers,


BioCardia, a clinical-stage regenerative medicine company headquartered in San Carlos, CA, develops novel therapies to improve the lives of patients suffering from cardiovascular diseases with largely unmet medical needs. The company is in the throes of its CardiAMP Cell Therapy Heart Failure Trial. I caught up with CEO Peter Altman to learn more about it.


Not everyone in your organization is an expert in the quality culture-related skill fields. We take a deep dive into why sustaining a positive quality culture by evolving the skills, expectations, and the connection with the patient is essential.


Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Five Steps To Great Results Using One-Step Multiplex RT-qPCR

One-step multiplex RT-qPCR is a technique used to rapidly quantify multiple targets directly from RNA in a single reaction. This blog explains the proper optimization and validation for successful one-step multiplex RT-qPCR as well as tips for choosing the right reagents for your needs.

A Checklist For Engineering Due Diligence In Pharma M&As

Pharmaceutical plants cannot be treated like real estate. Instead, they require a detailed assessment of where they are in “operational compliance and production readiness.”

The Evolution Of Biopharmaceutical Facility Designs

In the life cycle of pharmaceutical and biopharmaceutical commercial manufacturing, the one constant has been change. With the advent of modern therapeutics, large-scale commercial manufacturing became commonplace.

Digitization Of The Supply Chain: Challenges In Scaling Up Cell And Gene Therapy

This white paper discusses the unique biopharmaceutical supply chain challenges of cell and gene (C&G) therapy logistics and recommends forward-thinking solutions to address them. Successfully overcoming these logistics challenges is essential in order to scale up C&G therapies to treat large numbers of patients worldwide.

Rare Disease: Operationalizing Gene Therapy Trials

Even measured against the vast scientific mystery that defines the biotech industry, gene therapy poses extraordinary challenges. This paper explores the history of gene therapy trials, as well as the types of gene therapy vectors and delivery strategies. Also discussed is the regulatory and operational challenges associated with gene therapy trials, including start-up regulations, site selection, recruitment, and retention.

Extractables Testing On Single-Use Connectors

Appropriating BPOG testing on single-use connectors to mitigate the risks of extractables and leachables (E&L), as demonstrated in this article, is crucial to delivering safe and effective drugs.

The Future Of MilliporeSigma’s Gene Therapy CDMO Through The Lens Of History

On the road to becoming a global industry leader in cell and gene therapy, our viral vector manufacturing organization has undergone a major transformation over the last two decades. Marc Gaal, director of program management at MilliporeSigma, details the history of the business as well as some of the milestones achieved since its inception.

Choosing The Right CDMO For Late-Phase Clinical Trials

For many pharmaceutical companies that do not have their own facilities, choosing the right partner for late-phase clinical trials and commercial production is a critical aspect in the management of parenteral products. This webinar offers insight into the importance of looking for a partner with extensive experience in the parenteral arena, as products move through clinical phases and toward commercialization.

Reduce Product Variability, Control Temp Rates To Improve Cell Therapies

Reduced input variables and careful freeze/thaw cycles are critical in T-cell processing. Here, experts examine how these factors influence and optimize mononuclear cell enrichment and cryopreservation.